Skip to main content

Master of Public Health

Prostate Cancer, Version 1.2016.

AUTHORS

Mohler JL , Armstrong AJ , Bahnson RR , D'Amico AV , Davis BJ , Eastham JA , Enke CA , Farrington TA , Higano CS , Horwitz EM , Hurwitz M , Kane CJ , Kawachi MH , Kuettel M , Lee RJ , Meeks JJ , Penson DF , Plimack ER , Pow-Sang JM , Raben D , Richey S , Roach M , Rosenfeld S , Schaeffer E , Skolarus TA , Small EJ , Sonpavde G , Srinivas S , Strope SA , Tward J , Shead DA , Freedman-Cass DA , . Journal of the National Comprehensive Cancer Network : JNCCN. 2016 1 ; 14(1). 19-30
  • NIHMSID: 101162515

ABSTRACT

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel’s most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel’s most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

Tags: